Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an accompanying increase in white blood cells and platelets. It is the most prevalent myeloproliferative neoplasm (MPN), being the most common among these conditions and the only one associated with an increase in red blood cell production.

The total number of prevalent cases of polycythemia vera in the United States was around 182K cases in 2024. According to DelveInsight estimates, there were around 73K cases of asymptomatic polycythemia vera in the United States in 2024. 

Polycythemia vera currently has no cure, but treatments are available to manage the disease and its associated complications. A combination of procedures, medications, and other approaches may be required to control the condition. Two drugs have been approved for treating polycythemia vera: JAKAFI (ruxolitinib) and BESREMi (ropeginterferon alfa-2B/AOP2014/P1101), both of which are authorized for use in the US, Europe, and Japan.